Fatigue is a common complaint among patients with immune-mediated inflammatory diseases (IMIDs), but it is not well known as an adverse drug reaction (ADR) of biologics.

In this study, fatigue was the most frequently reported ADR of biologics by patients with IMIDs, and many of these patients described a pattern of recurring fatigue after biologic injection.

Evaluating the clinical pattern of fatigue may aid in understanding the potential contribution of a biologic in patients experiencing fatigue.